Results in response-adapted studies of reduced therapy in PET-negative groups
| Trial name . | Reference . | Stage . | No. of PET-negative patients . | No. of cycles and type of initial therapy . | % Interim PET negative . | 5-Point PET score (if used) . | No. of cycles and type of post-PET therapy . | Time to analysis (y) . | PFS (%) . | OS (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| NCRI RAPID | 1 | IA-IIA nonbulky | 420 | 3 ABVD | 75 | 1-2 | Nil vs IFRT | 5 | 90.8 vs 94.6 | 99 vs 97.1 |
| EORTC HD10 | 25 | I-II | 1 | |||||||
| Favorable risk | 381 | 2 ABVD | 86 | 1 ABVD + INRT vs 2 ABVD | 100 vs 94.9 | — | ||||
| Unfavorable risk | 519 | 75 | 2 ABVD + INRT vs 4 ABVD | 97.3 vs 94.7 | — | |||||
| RATHL | 2 | II with adverse features, III, IV | 935 | 2 ABVD | 84 | 1-3 | 4 ABVD | 3 | 85.7 | 97.2 |
| 4 AVD | 84.4 | 97.6 | ||||||||
| GITIL/FIL 0607 | 26 | II with adverse features, III, IV | 195 | 2 ABVD | 80 | 1-3 | 4 ABVD + IFRT | 2 | 94 | — |
| 4 ABVD | 88 | |||||||||
| GHSG HD15 | 27 | IIBX, III, IV | 548 | 6-8 BEACOPPescalated or 8 BEACOPP-14 | 74 (of partial responses) | No IFRT for PET negative | 4 | 92.6 | 95 | |
| LYSA AHL2011 | 28 | IIB, III, IV | 688 | 2 BEACOPPescalated | 88 | 4 BEACOPPescalated | 2 | 94 | — | |
| 4 ABVD | 92 |
| Trial name . | Reference . | Stage . | No. of PET-negative patients . | No. of cycles and type of initial therapy . | % Interim PET negative . | 5-Point PET score (if used) . | No. of cycles and type of post-PET therapy . | Time to analysis (y) . | PFS (%) . | OS (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| NCRI RAPID | 1 | IA-IIA nonbulky | 420 | 3 ABVD | 75 | 1-2 | Nil vs IFRT | 5 | 90.8 vs 94.6 | 99 vs 97.1 |
| EORTC HD10 | 25 | I-II | 1 | |||||||
| Favorable risk | 381 | 2 ABVD | 86 | 1 ABVD + INRT vs 2 ABVD | 100 vs 94.9 | — | ||||
| Unfavorable risk | 519 | 75 | 2 ABVD + INRT vs 4 ABVD | 97.3 vs 94.7 | — | |||||
| RATHL | 2 | II with adverse features, III, IV | 935 | 2 ABVD | 84 | 1-3 | 4 ABVD | 3 | 85.7 | 97.2 |
| 4 AVD | 84.4 | 97.6 | ||||||||
| GITIL/FIL 0607 | 26 | II with adverse features, III, IV | 195 | 2 ABVD | 80 | 1-3 | 4 ABVD + IFRT | 2 | 94 | — |
| 4 ABVD | 88 | |||||||||
| GHSG HD15 | 27 | IIBX, III, IV | 548 | 6-8 BEACOPPescalated or 8 BEACOPP-14 | 74 (of partial responses) | No IFRT for PET negative | 4 | 92.6 | 95 | |
| LYSA AHL2011 | 28 | IIB, III, IV | 688 | 2 BEACOPPescalated | 88 | 4 BEACOPPescalated | 2 | 94 | — | |
| 4 ABVD | 92 |
AVD, same as ABVD without bleomycin.